**AMENDMENTS TO THE CLAIMS:**

This listing of claims replaces all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. **(currently amended)** A combination product for delivery of a pharmacologically active substance, said combination product comprising:

(i) a positive oil in water emulsion ~~wherein said emulsion comprises~~comprising, at the oil-water interface, at least one cationic lipid selected from the group consisting of a $C_{10}$-$C_{24}$ alkylamine, a $C_{10}$-$C_{24}$ alkanolamine and a cholesterol ester, ~~at the oil-water interface,~~; and

(ii) an antibody,

wherein:

said at least one cationic lipid ~~compound~~ is linked to said antibody by a heterobifunctional linker, and

the pharmacologically active substance is incorporated in the oil in water emulsion.

2. **(currently amended)** The combination product of claim 1, wherein said combination product has a positive zeta charge.

3. **(cancelled)**

4. **(currently amended)** The combination product of claim ~~3~~ 2, wherein said at least one cationic lipid is stearylamine or oleylamine.

5. **(currently amended)** The combination product of claim 1, wherein said oil in water emulsion comprises ~~colloid~~ colloidal particles having an oily core surrounded by an interfacial film, wherein said interfacial film comprises said at least one cationic lipid, a nonionic surfactant and an anionic surfactant or anionic lipid, wherein said colloidal particles have a positive zeta potential.

6. **(currently amended)** The combination product of claim 5, wherein the pharmacologically active substance is incorporated in the oily core of the colloidal particles of said oil in water emulsion. ~~contains an active principle (drug).~~

7. **(previously presented)** The combination product of claim 1, wherein said antibody is a polyclonal antibody.

8. **(currently amended)** The combination product of claim 1, wherein said antibody is a monoclonal antibody selected

from the group consisting of ~~comprising~~ native forms, synthetic forms, chimeric forms and humanized forms.

9. **(previously presented)** The combination product of claim 1, wherein said antibody targets an antigen present at the surface of a pathological cell.

10. **(currently amended)** The combination product of claim 1, wherein said antibody targets a protein selected from the group consisting of ~~comprising~~ HER-2, H-ferritin, PSMA, mucins, MUC 1, CD 44 and retinal S-Ag.

11. **(previously presented)** The combination product of claim 1, wherein said antibody is AMB8LK antibody.

12. **(currently amended)** The combination product of claim 1, wherein said heterobiofunctional linker is ~~chosen from~~ N-1 stearyl-maleimide (SM), oleylmaleimide, succunimidyl, trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate (SMCC) ~~and~~or succinimidyl 3-(2-pyridyldithio)propionate (SPDP).

13. **(currently amended)** A method for producing ~~a~~ the combination product according to claim 1, said method comprising ~~the steps of~~:

a) optionally reducing an antibody in order to obtain free SH groups on its hinge region,

b) mixing a positive emulsion ~~wherein said emulsion comprises~~ comprising at least one cationic lipid presenting free $NH_2$ groups at its natural state, wherein said at least one cationic lipid is selected from the group consisting of a $C_{10}$-$C_{24}$ alkylamine, a $C_{10}$-$C_{24}$ alkanolamine, and a cholesterol ester~~, at its natural state~~, wherein said cationic lipid is linked to a heterobifunctional linker by said $NH_2$ groups, with the antibody presenting free SH groups in order to obtain said combination product.

**14. (currently amended)** The method of claim 13, wherein said positive emulsion in step b) is obtained by ~~emulsion~~:

i linking ~~a~~ the heterobifunctional linker to a free $NH_2$ group naturally present on ~~a~~ said at least one cationic lipid that is used to obtain a positive emulsion, in order to obtain a modified ~~compound~~ cationic lipid, and

ii mixing said modified cationic lipid~~, which at its natural state contains free $NH_2$ groups,~~ with water, oil and an emulsifying agent, in order to obtain a positive emulsion.

**15. (currently amended)** The method of claim 13, wherein said positive emulsion in step b) is obtained by:

~~i~~(i) mixing ~~a~~ said at least one cationic lipid, which at its natural state contains free $NH_2$ groups, with water, oil and an emulsifying agent in order to obtain a positive emulsion[[,]]; and

~~ii~~(ii) linking ~~a~~ said heterobifunctional linker to a free $NH_2$ group naturally present on said at least one cationic lipid, in order to obtain a modified cationic lipid within said positive emulsion.